$RFL
Rafael Holdings Inc Stock $rfl

$rfl Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000121390024022343 Filed on March 14, 2024

Income Statement

Concept	2024 Q1	2023 Q3
Revenue	$68.00K	$70.00K
YoY Change	-2.86%	1.45%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$310.5M	$1.400M
YoY Change	0.15%	-54.07%
% of Gross Profit
Research & Development	$612.0K	$1.270M
YoY Change	-72.49%	-31.02%
% of Gross Profit
Depreciation & Amortization	$38.00K	$20.00K
YoY Change	100.0%	-101.87%
% of Gross Profit
Operating Expenses	$311.1M	$2.680M
YoY Change	-0.36%	-45.38%
Operating Profit	-$3.143M
YoY Change	-26.2%
Interest Expense	$10.86M	$4.060M
YoY Change		2003.63%
% of Operating Profit
Other Income/Expense, Net	$25.00K
YoY Change
Pretax Income	$6.110M	$1.460M
YoY Change	-288.17%	-131.43%
Income Tax		$0.00
% Of Pretax Income		0.0%
Net Earnings	$6.047M	$1.220M
YoY Change	-285.95%	-125.5%
Net Earnings / Revenue	8892.65%	1742.86%
Basic Earnings Per Share	$0.26
Diluted Earnings Per Share	$0.25	$0.05
COMMON SHARES
Basic Shares Outstanding	23.64M shares
Diluted Shares Outstanding	24.40M shares

Balance Sheet

Concept	2024 Q1	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.70M	$79.21M
YoY Change	-19.32%	25.27%
Cash & Equivalents	$7.100M	$21.50M
Short-Term Investments	$64.60M	$57.71M
Other Short-Term Assets	$487.0K	$900.0K
YoY Change	-4.88%	-97.98%
Inventory
Prepaid Expenses
Receivables	$939.0K	$245.0K
Other Receivables	$1.924M	$1.900M
Total Short-Term Assets	$75.07M	$82.94M
YoY Change	-16.55%	-23.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.064M	$1.695M
YoY Change	19.17%	-4.24%
Goodwill	$3.571M
YoY Change
Intangibles	$1.888M	$0.00
YoY Change
Long-Term Investments	$21.94M	$12.60M
YoY Change	316.32%	140.41%
Other Assets	$42.00K	$9.000K
YoY Change	366.67%	-99.35%
Total Long-Term Assets	$31.08M	$15.89M
YoY Change	261.98%	59.31%
TOTAL ASSETS
Total Short-Term Assets	$75.07M	$82.94M
Total Long-Term Assets	$31.08M	$15.89M
Total Assets	$106.1M	$98.83M
YoY Change	7.71%	-16.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$509.0K	$333.0K
YoY Change	14.9%	-40.96%
Accrued Expenses	$845.0K	$763.0K
YoY Change	-36.27%	-59.31%
Deferred Revenue
YoY Change
Short-Term Debt	$1.700M	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.263M	$2.145M
YoY Change	65.97%	-89.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$87.00K	$55.00K
YoY Change	77.55%	-37.5%
Total Long-Term Liabilities	$87.00K	$55.00K
YoY Change	77.55%	-37.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.263M	$2.145M
Total Long-Term Liabilities	$87.00K	$55.00K
Total Liabilities	$3.895M	$2.200M
YoY Change	93.3%	-89.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$164.9M	-$167.3M
YoY Change	-1.31%	1.13%
Common Stock	$266.2M	$264.0M
YoY Change	3326887.5%	3300025.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$104.9M	$100.3M
YoY Change
Total Liabilities & Shareholders Equity	$106.1M	$98.83M
YoY Change	7.71%	-16.47%

Cashflow Statement

Concept	2024 Q1	2023 Q3
OPERATING ACTIVITIES
Net Income	$6.047M	$1.220M
YoY Change	-285.95%	-125.5%
Depreciation, Depletion And Amortization	$38.00K	$20.00K
YoY Change	100.0%	-101.87%
Cash From Operating Activities	-$2.529M	-$1.450M
YoY Change	-54.64%	-23.76%
INVESTING ACTIVITIES
Capital Expenditures	$11.00K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$2.780M	$7.410M
YoY Change	-63.06%	-214.67%
Cash From Investing Activities	-$2.791M	$7.410M
YoY Change	-62.92%	-216.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-932.0K	-40.00K
YoY Change	517.22%	-100.67%
NET CHANGE
Cash From Operating Activities	-2.529M	-1.450M
Cash From Investing Activities	-2.791M	7.410M
Cash From Financing Activities	-932.0K	-40.00K
Net Change In Cash	-6.252M	5.920M
YoY Change	-52.82%	-359.42%
FREE CASH FLOW
Cash From Operating Activities	-$2.529M	-$1.450M
Capital Expenditures	$11.00K	$0.00
Free Cash Flow	-$2.540M	-$1.450M
YoY Change	-54.44%	-27.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue		usd
CY2024Q1	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals		usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2064000	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-01-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55863
	dei	Entity Registrant Name EntityRegistrantName	RAFAEL HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2296593
	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Broad Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Newark
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07102
	dei	City Area Code CityAreaCode	(212)
	dei	Local Phone Number LocalPhoneNumber	658-1450
	dei	Security12b Title Security12bTitle	Class B common stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	RFL
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7136000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21498000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	64587000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	57714000	usd
CY2024Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	560000	usd
CY2023Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	387000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	245000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	245000	usd
CY2024Q1	us-gaap	Other Receivables OtherReceivables	379000	usd
CY2023Q3	us-gaap	Other Receivables OtherReceivables	213000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	487000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	914000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	294000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	75073000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	82941000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1695000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	3571000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1888000	usd
CY2024Q1	rfl	Inprocess Research And Development Noncurrent InprocessResearchAndDevelopmentNoncurrent	1575000	usd
CY2023Q3	rfl	Inprocess Research And Development Noncurrent InprocessResearchAndDevelopmentNoncurrent	1575000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9000	usd
CY2024Q1	us-gaap	Assets Assets	106149000	usd
CY2023Q3	us-gaap	Assets Assets	98829000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	509000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	333000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	845000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	763000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	140000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1023000	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1700000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3263000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2145000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	545000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	87000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	3895000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2200000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	266159000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	264010000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-164924000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167333000	usd
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	168000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-88000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-353000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	3714000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	3725000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	104939000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	100293000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	-2685000	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-3664000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	102254000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	96629000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106149000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	98829000	usd
CY2024Q1	us-gaap	Revenues Revenues	68000	usd
CY2023Q1	us-gaap	Revenues Revenues	70000	usd
	us-gaap	Revenues Revenues	136000	usd
	us-gaap	Revenues Revenues	140000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2561000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2085000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4601000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5194000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	612000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2225000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1101000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4306000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3143000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4259000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5621000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9401000	usd
CY2024Q1	us-gaap	Interest Income Other InterestIncomeOther	693000	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	562000	usd
	us-gaap	Interest Income Other InterestIncomeOther	1275000	usd
	us-gaap	Interest Income Other InterestIncomeOther	770000	usd
CY2023Q1	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals	67000	usd
	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals	223000	usd
CY2024Q1	rfl	Loss On Initial Investment In Day Three Upon Acquisition LossOnInitialInvestmentInDayThreeUponAcquisition	1633000	usd
	rfl	Loss On Initial Investment In Day Three Upon Acquisition LossOnInitialInvestmentInDayThreeUponAcquisition	1633000	usd
CY2024Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	399000	usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	139000	usd
	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	576000	usd
	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	154000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-46000	usd
	rfl	Realized Gain In Equity Investments Cyclo Therapeutics Inc RealizedGainInEquityInvestmentsCycloTherapeuticsInc	424000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9718000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	7594000	usd
CY2024Q1	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	51000	usd
CY2023Q1	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	378000	usd
	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	-115000	usd
	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	251000	usd
CY2024Q1	us-gaap	Other Income OtherIncome	25000	usd
	us-gaap	Other Income OtherIncome	118000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6110000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3247000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2572000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8449000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	usd
CY2024Q1	rfl	Equity In Losses Of Day Three Labs Inc EquityInLossesOfDayThreeLabsInc	206000	usd
	rfl	Equity In Losses Of Day Three Labs Inc EquityInLossesOfDayThreeLabsInc	422000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	5904000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3252000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2144000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8459000	usd
CY2023Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-157000	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-241000	usd
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	6784000	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-157000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	6543000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	5904000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3409000	usd
	us-gaap	Profit Loss ProfitLoss	2144000	usd
	us-gaap	Profit Loss ProfitLoss	-1916000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-143000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-159000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-265000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-258000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	6047000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3250000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2409000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1658000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	5904000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3409000	usd
	us-gaap	Profit Loss ProfitLoss	2144000	usd
	us-gaap	Profit Loss ProfitLoss	-1916000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	58000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	268000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	265000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	371000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-46000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	16000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	30000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	26000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	6008000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3157000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	2379000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1571000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-145000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-156000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-264000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-255000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6153000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3001000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2643000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1316000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.26
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.1
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.36
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.28
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.1
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.25
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.1
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.36
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.28
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.1
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23642421	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23155018	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23643660	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23085612	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24402069	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23155018	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24403308	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23085612	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	94512000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	5904000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	715000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	103000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	111000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	184000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1364000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1057000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	43000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	58000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1151000	usd
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	89000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	46000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	102254000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	96629000	usd
	us-gaap	Profit Loss ProfitLoss	2144000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1364000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	82000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	265000	usd
	rfl	Stock Issued During Period Value Sale Of Rafael Medical Devices Membership Units StockIssuedDuringPeriodValueSaleOfRafaelMedicalDevicesMembershipUnits	-925000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1151000	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	168000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	56000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-30000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	102254000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	99966000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3409000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	780000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	903000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	151000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	268000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-16000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	96535000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	97206000	usd
	us-gaap	Profit Loss ProfitLoss	-1916000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1959000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	902000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	157000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	371000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-26000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	96535000	usd
	us-gaap	Profit Loss ProfitLoss	2144000	usd
	us-gaap	Profit Loss ProfitLoss	-1916000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-6543000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2144000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8459000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	27000	usd
	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	-115000	usd
	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	251000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-46000	usd
	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	576000	usd
	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	154000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1052000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-220000	usd
	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals	223000	usd
	rfl	Loss On Initial Investment In Day Three Upon Acquisition LossOnInitialInvestmentInDayThreeUponAcquisition	1633000	usd
	rfl	Realized Gain In Equity Investments Cyclo Therapeutics Inc RealizedGainInEquityInvestmentsCycloTherapeuticsInc	424000	usd
	rfl	Unrealized Loss In Equity Investments Cyclo Therapeutics Inc UnrealizedLossInEquityInvestmentsCycloTherapeuticsInc	-7594000	usd
	rfl	Gain On Dissolution Of A Business GainOnDissolutionOfABusiness	18000	usd
	rfl	Equity In Loss Of Day Three Labs Inc2 EquityInLossOfDayThreeLabsInc2	422000	usd
	us-gaap	Provision For Other Losses ProvisionForOtherLosses	2000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	174000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-712000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-822000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	33000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	26000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-372000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-155000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-883000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	30000	usd
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	43000	usd
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-69000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	32000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	9000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4662000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7437000	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-687000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4662000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8124000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	105063000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	113137000	usd
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	100090000	usd
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	71383000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	70000	usd
	rfl	Proceeds From Investments Other Pharmaceuticals ProceedsFromInvestmentsOtherPharmaceuticals	42000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	271000	usd
	rfl	Purchase Of Investment In Cyclo Therapeutics Inc PurchaseOfInvestmentInCycloTherapeuticsInc	6786000	usd
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	1989000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-1299000	usd
	us-gaap	Proceeds From Decommissioning Fund ProceedsFromDecommissioningFund	2500000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-9577000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-41754000	usd
	rfl	Proceeds From Sale Of520 Property Discontinued Operations ProceedsFromSaleOf520PropertyDiscontinuedOperations	49400000	usd
	rfl	Payment To Fund Rp Finance Line Of Credit PaymentToFundRPFinanceLineOfCredit	1229000	usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	48171000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9577000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6417000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	800000	usd
	rfl	Payments For Taxes Related To Shares Withheld For Employee Taxes PaymentsForTaxesRelatedToSharesWithheldForEmployeeTaxes	82000	usd
	rfl	Payments For Taxes Related To Shares Withheld For Employee Taxes PaymentsForTaxesRelatedToSharesWithheldForEmployeeTaxes	157000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	168000	usd
	rfl	Proceeds From Sale Of Rmd Membership Units ProceedsFromSaleOfRMDMembershipUnits	925000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-125000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-157000	usd
	rfl	Payment Of Note Payable In Connection With Sale Of520 Property Discontinued Operations PaymentOfNotePayableInConnectionWithSaleOf520PropertyDiscontinuedOperations	15000000	usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-15000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-125000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15157000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14362000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16867000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21498000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26537000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7136000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9670000	usd
	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	34000	usd
	rfl	Other Receivable Recognized Related To Sale Of Patent OtherReceivableRecognizedRelatedToSaleOfPatent	210000	usd
	rfl	Consideration For Acquisition Of Day Three Included In Accrued Expenses ConsiderationForAcquisitionOfDayThreeIncludedInAccruedExpenses	200000	usd
	rfl	Elimination Of Principal And Accrued Interest On The Day Three Promissory Notes Included In Cons EliminationOfPrincipalAndAccruedInterestOnTheDayThreePromissoryNotesIncludedInCons	2000000	usd
CY2023Q1	us-gaap	Debt Current DebtCurrent	2000000	usd
CY2016	rfl	Effectivecancertherapybasedpercentage Effectivecancertherapybasedpercentage	0.95	pure
CY2023Q3	us-gaap	Other Ownership Interests Value OtherOwnershipInterestsValue	925000	usd
	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.42	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.</p>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7100000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	64600000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of Credit Risk and Significant Customers </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. For both the three and six months ended January 31, 2024, related parties represented 40% of the Company’s revenue. For the three and six months ended January 31, 2023, including revenue from discontinued operations, related parties represented 39% and 43% of the Company’s revenue, respectively. As of January 31, 2024, there was one customer which represented 12% of the Company’s accounts receivable balance and one related party which represented 45% of the Company's accounts receivable balance. As of July 31, 2023, there was one customer which represented 27% of the Company’s accounts receivable balance and one related party which represented 47% of the Company’s accounts receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Long-Lived Assets<b> </b></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, buildings, leasehold improvements, and furniture and fixtures are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives, which range as follows: </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Classification</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 89%; text-align: left">Building and improvements</td><td style="width: 1%"> </td> <td style="width: 9%; text-align: center">40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Tenant improvements</td><td> </td> <td style="text-align: center"><span style="font-size: 10pt">7-15</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Machinery and equipment</td><td> </td> <td style="text-align: center">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Other (primarily office equipment, furniture and fixtures)</td><td> </td> <td style="text-align: center">5</td><td style="text-align: left"> </td></tr> </table>
CY2022Q3	us-gaap	Property Plant And Equipment Owned Gross PropertyPlantAndEquipmentOwnedGross	49400000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2022Q3	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	49400000	usd
CY2024Q1	us-gaap	Other Notes Payable OtherNotesPayable	15000000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	33000000	usd
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	6800000	usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	49400000	usd
	us-gaap	Carrying Costs Property And Exploration Rights CarryingCostsPropertyAndExplorationRights	40200000	usd
	us-gaap	Other Restructuring Costs OtherRestructuringCosts	1200000	usd
CY2024Q1	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	1200000	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	44000000	usd
	rfl	Percentage Of Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent PercentageOfConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent	0.50	pure
	rfl	Ownership Interest Percentage OwnershipInterestPercentage	0.08	pure
CY2023Q1	us-gaap	Impaired Financing Receivable With Related Allowance Unpaid Principal Balance ImpairedFinancingReceivableWithRelatedAllowanceUnpaidPrincipalBalance	2000000	usd
CY2023Q1	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.075	pure
	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.11	pure
	srt	Interest Bearing Liabilities Average Rate Paid InterestBearingLiabilitiesAverageRatePaid	0.14	pure
	rfl	Promissory Note Interest Rate1 PromissoryNoteInterestRate1	0.18	pure
	rfl	Consideration For Acquisition Of Day Three Included In Accrued Expenses ConsiderationForAcquisitionOfDayThreeIncludedInAccruedExpenses	200000	usd
	rfl	Elimination Of Principal And Accrued Interest On The Day Three Promissory Notes Included In Cons EliminationOfPrincipalAndAccruedInterestOnTheDayThreePromissoryNotesIncludedInCons	2000000	usd
	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	742000	usd
CY2024Q1	us-gaap	Interest Income Interest Earning Asset InterestIncomeInterestEarningAsset	38000	usd
	us-gaap	Interest Income Interest Earning Asset InterestIncomeInterestEarningAsset	76000	usd
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	3142000	usd
	rfl	Percentage Of Issued And Outstanding Share PercentageOfIssuedAndOutstandingShare	0.12	pure
CY2024Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	0	usd
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	0	usd
CY2024Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	9375000	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	9375000	usd
CY2024Q1	rfl	Ownership Interests OwnershipInterests	0.375	pure
CY2023Q3	rfl	Ownership Interests OwnershipInterests	0.375	pure
CY2021Q1	us-gaap	Investment Maturity Date InvestmentMaturityDate	2021-09-01
CY2021Q3	us-gaap	Investment Interest Rate InvestmentInterestRate	0.15	pure
CY2021Q4	us-gaap	Investment Maturity Date InvestmentMaturityDate	2022-11-11
CY2024Q1	us-gaap	Investment Owned Percent Of Net Assets InvestmentOwnedPercentOfNetAssets	0.84	pure
CY2024Q1	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	8000	usd
CY2023Q1	us-gaap	Investment Owned Percent Of Net Assets InvestmentOwnedPercentOfNetAssets	0.95	pure
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	16000	usd
	rfl	Issued And Outstanding Ordinary Shares Percentage IssuedAndOutstandingOrdinarySharesPercentage	0.95	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.79	pure
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	200000	usd
	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	200000	usd
	us-gaap	Financing Receivable Accrued Interest Writeoff FinancingReceivableAccruedInterestWriteoff	2000000	usd
CY2024Q1	us-gaap	Interests Continued To Be Held By Transferor Fair Value InterestsContinuedToBeHeldByTransferorFairValue	700000	usd
	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	200000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	1499000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	63000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	77000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	408000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	3571000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	2180000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	362000	usd
CY2024Q1	rfl	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses	98000	usd
CY2024Q1	rfl	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Installment Note Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesInstallmentNotePayable	2500000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	545000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets	4293000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest	-1151000	usd
CY2024Q1	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	3142000	usd
CY2024Q1	us-gaap	Accounts Payable Interest Bearing Current And Noncurrent AccountsPayableInterestBearingCurrentAndNoncurrent	2500000	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1700000	usd
CY2024Q1	us-gaap	Goodwill Gross GoodwillGross	3600000	usd
CY2023Q2	rfl	Additional Shares AdditionalShares	2514970	shares
CY2023Q2	rfl	Warrant Purchase Shares WarrantPurchaseShares	2514970	shares
CY2023Q2	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.71
CY2023Q2	rfl	Aggregate Purchase Amount AggregatePurchaseAmount	2100000	usd
CY2023Q3	rfl	Additional Shares AdditionalShares	4000000	shares
CY2023Q3	rfl	Warrant Purchase Shares WarrantPurchaseShares	4000000	shares
CY2023Q3	rfl	Aggregate Purchase Amount AggregatePurchaseAmount	5000000000	usd
CY2023Q4	rfl	Common Shares CommonShares	2514970	shares
CY2023Q4	rfl	Additional Shares AdditionalShares	2766467	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.40	pure
CY2024Q1	rfl	Unrealized Loss In Equity Investments Cyclo Therapeutics Inc UnrealizedLossInEquityInvestmentsCycloTherapeuticsInc	9700000	usd
	rfl	Unrealized Loss In Equity Investments Cyclo Therapeutics Inc UnrealizedLossInEquityInvestmentsCycloTherapeuticsInc	-7600000	usd
	rfl	Total Aggregate Fair Value TotalAggregateFairValue	19567187000	usd
CY2023Q3	rfl	Total Aggregate Fair Value TotalAggregateFairValue	4763102000	usd
	rfl	Amortized Cost AmortizedCost	64599000	usd
	rfl	Gross Unrealized Gains GrossUnrealizedGains	4000	usd
	rfl	Gross Unrealizedlosses GrossUnrealizedlosses	-16000	usd
	rfl	Fair Value FairValue	64587000	usd
	rfl	Amortized Cost AmortizedCost	57988000	usd
	rfl	Gross Unrealized Gains GrossUnrealizedGains	4386000	usd
	rfl	Gross Unrealizedlosses GrossUnrealizedlosses	-4660000	usd
	rfl	Fair Value FairValue	57714000	usd
CY2024Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	399000	usd
	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	576000	usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	139000	usd
	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	154000	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	88447000	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	69676000	usd
CY2024Q1	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	0	usd
CY2023Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	65000	usd
CY2024Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	343000	usd
CY2023Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	247000	usd
CY2024Q1	rfl	Accounts Receivable Related Party AccountsReceivableRelatedParty	281000	usd
CY2023Q3	rfl	Accounts Receivable Related Party AccountsReceivableRelatedParty	211000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	245000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	245000	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	379000	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	213000	usd
CY2024Q1	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	2505000	usd
CY2023Q3	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	2505000	usd
CY2024Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	412000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	59000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	68000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2976000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2573000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	912000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	878000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2064000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1695000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41000	usd
	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	3571000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	3571000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1900000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1888000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	86000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	148000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	132000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	123000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	123000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1276000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1888000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12000	usd
CY2024Q1	rfl	Stock Options Excluded From Anti Diluted StockOptionsExcludedFromAntiDiluted	638409	shares
CY2023Q1	rfl	Stock Options Excluded From Anti Diluted StockOptionsExcludedFromAntiDiluted	953347	shares
	rfl	Stock Options Excluded From Anti Diluted StockOptionsExcludedFromAntiDiluted	638409	shares
	rfl	Stock Options Excluded From Anti Diluted StockOptionsExcludedFromAntiDiluted	953347	shares
CY2023Q1	rfl	Shares Issuable Upon Vesting Of Restricted Stock SharesIssuableUponVestingOfRestrictedStock	994179	shares
	rfl	Shares Issuable Upon Vesting Of Restricted Stock SharesIssuableUponVestingOfRestrictedStock	994179	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	638409	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1947526	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	638409	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1947526	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	5904000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3252000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2144000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8459000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-143000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-159000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-265000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-258000	usd
CY2024Q1	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable	6047000	usd
CY2023Q1	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable	-3093000	usd
	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable	2409000	usd
	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable	-8201000	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-157000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	6543000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	6047000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3250000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2409000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1658000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23642421	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23155018	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23643660	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23085612	shares
CY2024Q1	us-gaap	Dilutive Securities DilutiveSecurities	759648000	usd
	us-gaap	Dilutive Securities DilutiveSecurities	759648000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24402069	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23155018	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24403308	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23085612	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.26
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.1
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.36
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.28
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.1
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.25
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.1
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.36
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.28
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.1
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2024Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	69000	usd
CY2023Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	20000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	147000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	88000	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	69000	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	0	usd
CY2024Q1	us-gaap	Area Of Land AreaOfLand	80000	sqft
CY2023Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	27000	usd
CY2024Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	27000	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	54000	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	156000	usd
CY2023Q1	us-gaap	Interest Receivable InterestReceivable	2000000	usd
CY2023Q1	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.075	pure
CY2024Q1	us-gaap	Long Term Debt Maturity Date LongTermDebtMaturityDate	2024-03-13
CY2023Q1	us-gaap	Cash Including Discontinued Operations CashIncludingDiscontinuedOperations	19000	usd
CY2024Q1	rfl	Revenue Percentage RevenuePercentage	0.40	pure
CY2023Q1	rfl	Revenue Percentage RevenuePercentage	0.43	pure
	rfl	Revenue Percentage RevenuePercentage	0.40	pure
	rfl	Revenue Percentage RevenuePercentage	0.43	pure
CY2022Q3	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	3225806	shares
CY2022Q3	rfl	Aggregate Price Per Share AggregatePricePerShare	1.86
CY2022Q3	rfl	Aggregtae Sale Price AggregtaeSalePrice	6000000	usd
CY2023Q3	rfl	Aggregate Voting Percentage AggregateVotingPercentage	0.513	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	70000000	shares
CY2023Q1	rfl	Amount Of Aggregate Purchase Price AmountOfAggregatePurchasePrice	2100000	usd
CY2023Q1	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.95	pure
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	16000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	5000	usd
CY2024Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	6100000	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-3200000	usd
	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	6000	usd
	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	10000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	2600000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-8400000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	545000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2024Q1	rfl	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2023Q1	rfl	Total Revenue Percentage TotalRevenuePercentage	1	pure
	rfl	Total Revenue Percentage TotalRevenuePercentage	1	pure
	rfl	Total Revenue Percentage TotalRevenuePercentage	0.36	pure
	rfl	Restricted Stock Units Description RestrictedStockUnitsDescription	On August 24, 2021, the Company issued 2,833,425 shares of Class B common stock (the “Institutional Shares”), par value $0.01 per share, to the Institutional Investors, at a purchase price equal to $35.00 per share, for aggregate gross proceeds of approximately $99.2 million, before deducting placement agent fees and other offering expenses.
CY2021Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	98000000	usd
CY2021Q3	rfl	Deducting Transaction Costs DeductingTransactionCosts	6200000	usd
CY2022Q3	rfl	Aggregate Sale Price AggregateSalePrice	6000000	usd
CY2022Q2	rfl	Employment Agreement Term EmploymentAgreementTerm	P5Y
CY2022Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	600000000	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	290000000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	388409	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.51
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M15D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	250000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.78
	rfl	Weighted Average Remaining Contractual Termin Years Granted WeightedAverageRemainingContractualTerminYearsGranted	P10Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	638409	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.52
	rfl	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P8Y10M20D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	114602	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.13
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y1M6D
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	46125	shares
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	228000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M
CY2022Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	33360	shares
CY2022Q1	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	986835	shares
CY2022Q1	rfl	Restricted Shares Vested Percentage RestrictedSharesVestedPercentage	0.24	pure
CY2022Q2	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	452130	shares
CY2024Q1	us-gaap	Selling Expense SellingExpense	307913000	usd
	us-gaap	Selling Expense SellingExpense	307913000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	915000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	915000	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	111408	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	135000	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	101402	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	684766	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.22
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	347810	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.83
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	272928	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.13
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	759648	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.36
CY2024Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	667000	usd
CY2023Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	884000	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1175000	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1967000	usd
CY2024Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	48000	usd
CY2023Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	43000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	189000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	140000	usd
CY2023Q1	rfl	Forfeiture Of Rs Us Within General And Administrative ForfeitureOfRSUsWithinGeneralAndAdministrative	-931000	usd
	rfl	Forfeiture Of Rs Us Within General And Administrative ForfeitureOfRSUsWithinGeneralAndAdministrative	-931000	usd
CY2023Q1	rfl	Forfeiture Of Rs Us Within Research And Development ForfeitureOfRSUsWithinResearchAndDevelopment	-119000	usd
	rfl	Forfeiture Of Rs Us Within Research And Development ForfeitureOfRSUsWithinResearchAndDevelopment	-119000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	715000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-123000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1364000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1057000	usd
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	22.91
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company is the lessor of the Israeli property which is leased to tenants under net operating leases with a term expiration date within 2025.
CY2024Q1	us-gaap	Revenues Revenues	68000	usd
CY2023Q1	us-gaap	Revenues Revenues	70000	usd
	us-gaap	Revenues Revenues	136000	usd
	us-gaap	Revenues Revenues	140000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	38000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	78000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	116000	usd
	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	A related party has the right to terminate the Israeli lease upon four months’ notice.
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	29200000	usd
	us-gaap	Long Term Debt Average Amount Outstanding LongTermDebtAverageAmountOutstanding	2100000	usd
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	32197679	shares
	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	0.97
CY2024Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	6067306	shares
CY2024Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	1500000	usd
	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	1546391	shares
CY2024Q1	us-gaap	Line Of Credit LineOfCredit	21900000	usd
CY2024Q1	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	3658368	shares
	rfl	Outstanding Shares Issued Percentage OutstandingSharesIssuedPercentage	0.06	pure
	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi		usd
	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals		usd
CY2023Q1	rfl	Loss On Initial Investment In Day Three Upon Acquisition LossOnInitialInvestmentInDayThreeUponAcquisition		usd
	rfl	Loss On Initial Investment In Day Three Upon Acquisition LossOnInitialInvestmentInDayThreeUponAcquisition		usd
CY2024Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2024Q1	rfl	Realized Gain In Equity Investments Cyclo Therapeutics Inc RealizedGainInEquityInvestmentsCycloTherapeuticsInc		usd
CY2023Q1	rfl	Realized Gain In Equity Investments Cyclo Therapeutics Inc RealizedGainInEquityInvestmentsCycloTherapeuticsInc		usd
	rfl	Realized Gain In Equity Investments Cyclo Therapeutics Inc RealizedGainInEquityInvestmentsCycloTherapeuticsInc		usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2023Q1	us-gaap	Other Income OtherIncome		usd
	us-gaap	Other Income OtherIncome		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	rfl	Equity In Losses Of Day Three Labs Inc EquityInLossesOfDayThreeLabsInc		usd
	rfl	Equity In Losses Of Day Three Labs Inc EquityInLossesOfDayThreeLabsInc		usd
CY2024Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax		usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax		usd
CY2024Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
CY2023Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals		usd
	rfl	Loss On Initial Investment In Day Three Upon Acquisition LossOnInitialInvestmentInDayThreeUponAcquisition		usd
	rfl	Realized Gain In Equity Investments Cyclo Therapeutics Inc RealizedGainInEquityInvestmentsCycloTherapeuticsInc		usd
	rfl	Unrealized Loss In Equity Investments Cyclo Therapeutics Inc UnrealizedLossInEquityInvestmentsCycloTherapeuticsInc		usd
	rfl	Gain On Dissolution Of A Business GainOnDissolutionOfABusiness		usd
	rfl	Equity In Loss Of Day Three Labs Inc2 EquityInLossOfDayThreeLabsInc2		usd
	us-gaap	Provision For Other Losses ProvisionForOtherLosses		usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	rfl	Proceeds From Investments Other Pharmaceuticals ProceedsFromInvestmentsOtherPharmaceuticals		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	rfl	Purchase Of Investment In Cyclo Therapeutics Inc PurchaseOfInvestmentInCycloTherapeuticsInc		usd
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Proceeds From Decommissioning Fund ProceedsFromDecommissioningFund		usd
	rfl	Proceeds From Sale Of520 Property Discontinued Operations ProceedsFromSaleOf520PropertyDiscontinuedOperations		usd
	rfl	Payment To Fund Rp Finance Line Of Credit PaymentToFundRPFinanceLineOfCredit		usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	rfl	Proceeds From Sale Of Rmd Membership Units ProceedsFromSaleOfRMDMembershipUnits		usd
	rfl	Payment Of Note Payable In Connection With Sale Of520 Property Discontinued Operations PaymentOfNotePayableInConnectionWithSaleOf520PropertyDiscontinuedOperations		usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1		usd
	rfl	Other Receivable Recognized Related To Sale Of Patent OtherReceivableRecognizedRelatedToSaleOfPatent		usd
	rfl	Consideration For Acquisition Of Day Three Included In Accrued Expenses ConsiderationForAcquisitionOfDayThreeIncludedInAccruedExpenses		usd
	rfl	Elimination Of Principal And Accrued Interest On The Day Three Promissory Notes Included In Cons EliminationOfPrincipalAndAccruedInterestOnTheDayThreePromissoryNotesIncludedInCons		usd
CY2023Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross		usd
CY2023Q3	us-gaap	Goodwill Goodwill		usd
CY2024Q1	rfl	Shares Issuable Upon Vesting Of Restricted Stock SharesIssuableUponVestingOfRestrictedStock		shares
	rfl	Shares Issuable Upon Vesting Of Restricted Stock SharesIssuableUponVestingOfRestrictedStock		shares
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2023Q1	us-gaap	Dilutive Securities DilutiveSecurities		usd
	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2024Q1	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	rfl	Aggregate Intrinsic Value Outstanding Granted AggregateIntrinsicValueOutstandingGranted		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	rfl	Weighted Averag Remaining Contractual Term Outstanding Expired WeightedAveragRemainingContractualTermOutstandingExpired
CY2024Q1	rfl	Aggregate Intrinsic Value Outstanding Expired AggregateIntrinsicValueOutstandingExpired		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	rfl	Weighted Average Remaining Contractual Termin Years Cancelled Forfeited WeightedAverageRemainingContractualTerminYearsCancelledForfeited
CY2024Q1	rfl	Aggregate Intrinsic Value Cancelled Forfeited AggregateIntrinsicValueCancelledForfeited		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q1	rfl	Forfeiture Of Rs Us Within General And Administrative ForfeitureOfRSUsWithinGeneralAndAdministrative		usd
	rfl	Forfeiture Of Rs Us Within General And Administrative ForfeitureOfRSUsWithinGeneralAndAdministrative		usd
CY2024Q1	rfl	Forfeiture Of Rs Us Within Research And Development ForfeitureOfRSUsWithinResearchAndDevelopment		usd
	rfl	Forfeiture Of Rs Us Within Research And Development ForfeitureOfRSUsWithinResearchAndDevelopment		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001713863

Files In Submission

Name	View Source	Status
0001213900-24-022343-index-headers.html	Edgar Link	pending
0001213900-24-022343-index.html	Edgar Link	pending
0001213900-24-022343.txt	Edgar Link	pending
0001213900-24-022343-xbrl.zip	Edgar Link	pending
ea0201606-10q_rafaelhold.htm	Edgar Link	pending
ea020160601ex31-1_rafaelhold.htm	Edgar Link	pending
ea020160601ex31-2_rafaelhold.htm	Edgar Link	pending
ea020160601ex32-1_rafaelhold.htm	Edgar Link	pending
ea020160601ex32-2_rafaelhold.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
report.css	Edgar Link	pending
rfl-20240131.xsd	Edgar Link	pending
rfl-20240131_def.xml	Edgar Link	unprocessable
rfl-20240131_lab.xml	Edgar Link	unprocessable
rfl-20240131_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
rfl-20240131_cal.xml	Edgar Link	unprocessable
ea0201606-10q_rafaelhold_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RFL
Rafael Holdings Inc Stock $rfl

2024 Q1 Form 10-Q Financial Statement

#000121390024022343 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RFL Rafael Holdings Inc Stock $rfl

2024 Q1 Form 10-Q Financial Statement

#000121390024022343 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RFL
Rafael Holdings Inc Stock $rfl